| 9/8/2010 |
Hemispherx Biopharma to Present at the Rodman and Renshaw 12th Annual Healthcare Conference
|
| 9/8/2010 |
HEMISPHERX BIOPHARMA TO PRESENT NEW RETROVIRUS (XMRV) DATA AT 1ST INTERNATIONAL WORKSHOP ON XMRV
AND CHRONIC FATIGUE SYNDROME (CFS)
…Retrovirus Positive CFS Patients Show Enhanced Response to Ampligen®, An Experimental Therapeutic, Relative to XMRV Negative Group
|
| 8/24/2010 |
HEMISPHERX SETTLES ALL SECURITIES CLASS ACTIONS Title
|
| 8/18/2010 |
Hemispherx Biopharma Awarded $188 Million Judgment against JCI
…Culmination of 6 Year Litigation Battle In U.S. Federal Courts
|
| 8/6/2010 |
HEMISPHERX BIOPHARMA, INC. 2nd QUARTER 2010 FINANCIAL RESULTS
…Drug / Biologic Development Progress in North America, India and Japan
|
| 7/19/2010 |
The Indian Drugs Controller General Approves Start of Clinical Study of Hemispherx Biopharma’s Natural Interferon Product, Alferon N Injection®, in Hospitalized Flu Patients
. . . Clinical Sites Expected to Enroll Subjects During Monsoon Season
|
| 7/15/2010 |
Hemispherx Publishes Full Report of Three Year Joint Research Program at Japanese NIID
…..Full Report Setting Stage for Clinical Testing of Novel Flu Vaccine/Ampligen® Combination Now Available on Hemispherx’s Website
|
| 7/12/2010 |
Hemispherx Reports Successful Culmination of Three Year Joint Research Program at Japanese NIID
…..Sets Stage for Clinical Testing of Novel Flu Vaccine/Ampligen® Combination.
|
| 6/15/2010 |
Hemispherx Biopharma Licenses Platform Technologies to GP Pharm
.…Initial Commercial Target is Chronic Fatigue Syndrome in Latin America
|
| 5/17/2010 |
Hemispherx Biopharma Prepares Application to Initiate Phase II
Clinical Trials in China with Ampligen®
. . . Proposed Trial to Address Seriously Ill Patients with Influenza
|
